Nucleot(s)ide Analogs for Chronic Hepatitis Virus Therapy: A Global Bibliometric Analysis (1986-2022)
DOI:
https://doi.org/10.3329/bjms.v23i3.75098Keywords:
Chronic Hepatitis Virus, Global BibliometricAbstract
Objectives: This study aimed to analyze the global profile of the nucleotide/nucleoside analogs (NAs) for chronic hepatitis virus therapy-related research.
Background: NAs, which closely resemble the structure of naturally occurring nucleotides/nucleosides, function by disrupting the elongation of the nascent DNA strand. These compounds are considered safe and well-tolerated, as they specifically target viral, but not human, polymerases involved in DNA replication. NAs are crucial in treating viral infections, including hepatitis, and are widely used due to their efficacy and safety. However, a study about trends in NAs for chronic hepatitis therapy-related research was never reported before.
Methods: The NAs for chronic hepatitis therapy-related research bibliometric analysis was performed on articles indexed in the Scopus database from 1986 to 2022.
Results: The total number of articles published worldwide is 2,341 documents, with an annual average of 65 documents. The United States generated the most articles (n = 486), followed by China (n = 454), France (n = 191), and Italy (n = 179). Since 1992, the number of publications has increased dramatically worldwide. Globally, liver cell carcinoma, antiviral therapy, hepatitis B (e) antigen, and alanine aminotransferase are becoming hot research topics in the field.
Conclusions: This study provides a unique composite picture of NAs for chronic hepatitis therapy-related research worldwide and evaluates research productivity from 1986 to 2022. This finding suggests that the prospects for interventions in chronic hepatitis remain promising.
Bangladesh Journal of Medical Science Vol. 23 No. 03 July’24 Page : 747-756
Downloads
210
300
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Wahyu Aristyaning Putri
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in the Bangladesh Journal of Medical Science agree to the following terms that:
- Authors retain copyright and grant Bangladesh Journal of Medical Science the right of first publication of the work.
Articles in Bangladesh Journal of Medical Science are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0.This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.- Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.